Company Overview
| Stock Name | Ocumension-B |
|---|---|
| Stock Code | 01477 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國眼科醫藥平台公司,致力於識別、開發和商業化同類首創或同類最佳的眼科療法,提供世界一流的藥物整體解決方案,以滿足中國眼科醫療的巨大需求缺口。 |
| Listing Date | 2020-07-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市靜安區石門一路211號旺旺大廈502-1室 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | ocumension.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 14.66 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 7,330 |
| Par Value | To be extracted |
| Offer Period | 2020-06-29 to 2020-07-03 |
| Global Offering Shares | 105,930,000 shares |
| HK Public Offer Shares (Initial) | 10,593,000 shares (10.0%) |
| Public Offer Lots (Initial) | 21,186lots (Pool A10,593lots,Pool B10,593lots) |
| International Placing Shares (Initial) | 95,337,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 575,250,620 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,552,933,800 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 7,330 |
| 2 lots | 1,000 | HK$ 14,660 |
| 3 lots | 1,500 | HK$ 21,990 |
| 4 lots | 2,000 | HK$ 29,320 |
| 5 lots | 2,500 | HK$ 36,650 |
| 6 lots | 3,000 | HK$ 43,980 |
| 7 lots | 3,500 | HK$ 51,310 |
| 8 lots | 4,000 | HK$ 58,640 |
| 9 lots | 4,500 | HK$ 65,970 |
| 10 lots | 5,000 | HK$ 73,300 |
| 12 lots | 6,000 | HK$ 87,960 |
| 14 lots | 7,000 | HK$ 102,620 |
| 16 lots | 8,000 | HK$ 117,280 |
| 18 lots | 9,000 | HK$ 131,940 |
| 20 lots | 10,000 | HK$ 146,600 |
| 30 lots | 15,000 | HK$ 219,900 |
| 40 lots | 20,000 | HK$ 293,200 |
| 50 lots | 25,000 | HK$ 366,500 |
| 60 lots | 30,000 | HK$ 439,800 |
| 70 lots | 35,000 | HK$ 513,100 |
| 80 lots | 40,000 | HK$ 586,400 |
| 90 lots | 45,000 | HK$ 659,700 |
| 100 lots | 50,000 | HK$ 733,000 |
| 120 lots | 60,000 | HK$ 879,600 |
| 140 lots | 70,000 | HK$ 1,026,200 |
| 160 lots | 80,000 | HK$ 1,172,800 |
| 180 lots | 90,000 | HK$ 1,319,400 |
| 200 lots | 100,000 | HK$ 1,466,000 |
| 300 lots | 150,000 | HK$ 2,199,000 |
| 400 lots | 200,000 | HK$ 2,932,000 |
| 500 lots | 250,000 | HK$ 3,665,000 |
| 600 lots | 300,000 | HK$ 4,398,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 700 lots | 350,000 | HK$ 5,131,000 |
| 800 lots | 400,000 | HK$ 5,864,000 |
| 900 lots | 450,000 | HK$ 6,597,000 |
| 1,000 lots | 500,000 | HK$ 7,330,000 |
| 1,200 lots | 600,000 | HK$ 8,796,000 |
| 1,400 lots | 700,000 | HK$ 10,262,000 |
| 1,600 lots | 800,000 | HK$ 11,728,000 |
| 1,800 lots | 900,000 | HK$ 13,194,000 |
| 2,000 lots | 1,000,000 | HK$ 14,660,000 |
| 4,000 lots | 2,000,000 | HK$ 29,320,000 |
| 6,000 lots | 3,000,000 | HK$ 43,980,000 |
| 8,000 lots | 4,000,000 | HK$ 58,640,000 |
| 10,593 lots | 5,296,500 | HK$ 77,646,690 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 4.84B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +100% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,433,174,089 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损净额人民币1,325.5百万元 |
| Period-End Cash Balance | 人民币192.4百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 0 | 812 |
| Cost of sales | 0 | -802 |
| Gross profit | 0 | 813 |
| Other income and gains, net | 856 | 8,537 |
| Selling and distribution expenses | 0 | -8,459 |
| Administrative expenses | -8,659 | -58,785 |
| Operating profit | -895,955 | -945,855 |
| Net finance costs | -965 | -963 |
| Profit before tax | -995,956 | -946,885 |
| Income tax expense | 0 | 0 |
| Profit for the year | -975,966 | -936,785 |
| Profit attributable to owners | -973,964 | -923,815 |
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 83,629 | 983,814 |
| Trade and bills receivables | 8,469 | 83,581 |
| Inventories | 864 | 8,259 |
| Total current assets | 93,596 | 937,994 |
| Total assets | 953,884 | 954,984 |
| Total current liabilities | 8,444 | 843,784 |
| Total liabilities | 834,934 | 9,258,734 |
| Total equity | -793,034 | -9,130,438 |
| Equity attributable to owners | -914,024 | -9,210,428 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | -96,254 | -97,284 |
| Net cash from investing activities | -74,664 | -717,917 |
| Net cash from financing activities | 116,091 | 1,140,655 |
| Net increase in cash | 45,707 | 153,030 |
| Depreciation of PP&E | 15 | 250 |
| Depreciation of right-of-use assets | 49 | 958 |
| Purchase of PP&E | -278 | -766 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 37.0 |
|---|---|
| First Day Open | HK$ 43.0 |
| First Day Change | 152.39% |
| First Day Volume | 59068800.0 |
| First Day Turnover | 2394770000.0 |
| Use of Proceeds | 1、約427.19百萬港元(即所得款項凈額的30.00%)將用于我們的核心產品OT401;
2、約711.98百萬港元(即所得款項凈額的50.00%)將用于其他候選藥物;
3、約142.40百萬港元(即所得款項凈額的10.00%)將用于根據我們與當地政府所訂合作協議收購蘇州的制造設施;
4、約142.40百萬港元(即所得款項凈額的10.00%)將用作營運資金及用于其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Alpha Profit Holdings Limited | 116,231,810 HKD | — | 7.48% | — | 6 months | 2021-01-10 |
| 2 | BlackRock Funds | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 3 | Boyu Capital Opportunities Master Fund | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 4 | Cormorant Asset Management, LP | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 5 | Fidelity International | 139,475,240 HKD | — | 8.98% | — | 6 months | 2021-01-10 |
| 6 | General Atlantic Singapore OT Pte. Ltd. | 77,485,430 HKD | — | 4.99% | — | 6 months | 2021-01-10 |
| 7 | HBM Healthcare Investments (Cayman) Ltd. | 23,243,430 HKD | — | 1.50% | — | 6 months | 2021-01-10 |
| 8 | Hudson Bay Master Fund LTD | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 9 | Lake Bleu Prime Healthcare Master Fund Limited | 54,242,000 HKD | — | 3.49% | — | 6 months | 2021-01-10 |
| 10 | Octagon Investments Master Fund LP | 15,495,620 HKD | — | 1.00% | — | 6 months | 2021-01-10 |
| 11 | OrbiMed Funds | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 12 | Rock Springs Capital Master Fund LP | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 13 | SCC Growth V Holdco L, Ltd. | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 14 | TLS Beta Pte. Ltd. | 77,485,430 HKD | — | 4.99% | — | 6 months | 2021-01-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳連勇 | — |
| Company Secretary | 季芸、孫佩真 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 6 Dimensions Capital持股21.55%,蘇州通和二期持股15.88%,Summer Iris Limited持股13.60%,TLS Beta Pte. Ltd.持股9.47%,蘇州通和毓承持股6.81%等。 |
|---|




